ArticleJACC. Case reports2025
Management of Cardiac Amyloidosis With Concomitant Left Ventricular Outflow Tract Obstruction.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Pathogenesis, screening, and diagnosis of hypertrophic cardiomyopathy.BMJ medicine · 2026Review
- Hereditary Transthyretin Cardiac Amyloidosis With Severe Left Ventricular Outflow Tract Obstruction Mimicking Hypertrophic Obstructive Cardiomyopathy.JACC. Case reports · 2026Article
- Challenges in diagnosis and management of severe aortic stenosis with coexisting cardiac amyloidosis: a case report.European heart journal. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac amyloidosis (CA) is a highly morbid cause of heart failure with a poor untreated prognosis. The presence of left ventricular outflow tract (LVOT) obstruction may lead to misclassification of CA as hypertrophic obstructive cardiomyopathy (HOCM). Between 2022 and 2024, 7 patients-4 with light- chain cardiac amyloidosis (AL-CM) and 3 with transthyretin cardiac amyloidosis-initially presented with HOCM at our center (The Johns Hopkins Hospital, Baltimore, Maryland, USA). Diagnostic delay from HOCM to CA diagnosis ranged from 0 to 34 months. Patients with AL-CM had advanced disease (revised Mayo stage III) at the time of CA diagnosis. Six patients required reduction or withdrawal of therapy used for symptomatic LVOT obstruction, and 3 patients were referred for septal reduction therapy. Screening for CA should be considered in older adult patients presenting with HOCM. Symptomatic management of CA with LVOT obstruction is complex given patients' poor tolerance of negatively inotropic medications and the high burden of orthostatic hypotension in patients with CA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.